Last reviewed · How we verify

Aspirin 80

Shiraz University of Medical Sciences · FDA-approved active Small molecule

Aspirin 80 is a Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Small molecule drug developed by Shiraz University of Medical Sciences. It is currently FDA-approved for Acute myocardial infarction prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.

Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation.

Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation. Used for Acute myocardial infarction prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.

At a glance

Generic nameAspirin 80
SponsorShiraz University of Medical Sciences
Drug classNonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent
TargetCyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of thromboxane A2 in platelets, which is essential for platelet activation and clot formation. At low doses (such as 80 mg), aspirin preferentially affects platelet function, making it effective for antiplatelet therapy without significantly inhibiting protective prostaglandins in the gastrointestinal tract.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aspirin 80

What is Aspirin 80?

Aspirin 80 is a Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent drug developed by Shiraz University of Medical Sciences, indicated for Acute myocardial infarction prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.

How does Aspirin 80 work?

Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation.

What is Aspirin 80 used for?

Aspirin 80 is indicated for Acute myocardial infarction prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention, Stable angina pectoris.

Who makes Aspirin 80?

Aspirin 80 is developed and marketed by Shiraz University of Medical Sciences (see full Shiraz University of Medical Sciences pipeline at /company/shiraz-university-of-medical-sciences).

What drug class is Aspirin 80 in?

Aspirin 80 belongs to the Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class. See all Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid-antiplatelet-agent.

What development phase is Aspirin 80 in?

Aspirin 80 is FDA-approved (marketed).

What are the side effects of Aspirin 80?

Common side effects of Aspirin 80 include Gastrointestinal bleeding, Dyspepsia, Nausea, Hemorrhagic stroke, Allergic reactions.

What does Aspirin 80 target?

Aspirin 80 targets Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) and is a Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing